Else Marit Inderberg
- Senior Scientist; PhD
- +47 22 78 23 17
Group leader & Head of Immunomonitoring
Education:
2008-2011: PhD in Tumour Immunology (Faculty of Medicine,University of Oslo, Norway) Cancer vaccines and cancer-specific T-cell receptors; Development of novel immunotherapies
2002-2005 : Diplôme EPHE Immunology (LEcole Pratique des Hautes Etudes, Sorbonne, Paris, France) «Development of an inducible melanoma model expressing a defined tumour antigen and its immunological characterisation »
1996-1998: BSc (Honours) Biochemistry University of Reading, UK
Research interests/projects:
Immunomonitoring facility for verification of treatment effects and mechanisms as well as biomarker discovery and development of novel immunotherapies
- Detection of immune responses in patient samples pre- and post immunotherapy treatment.
- Detection and discovery of immunotherapy biomarkers
- Therapeutic TCR discovery and pre-clinical validation
- Chimeric Antigen Receptors (CAR) discovery and pre-clinical validation
- Discovery and pre-clinical validation of vaccination targets
- Development of novel technologies to improve cell-based therapy
Work experience
2013-present: Head of Immunomonitoring and Postdoctoral Fellow, Dept. of Cellular Therapy, OUS-Radiumhospitalet, Oslo, Norway
2011-2012: Research Fellow, Institute for Cancer Research, OUS- Radiumhospitalet, Norway
2008-2011: PhD student, Section for Immunotherapy, Institute for Cancer Research, OUS- Radiumhospitalet, Norway
2005-2008: Research assistant, Dept. of Immunology, Institute for Cancer Research, OUS-Radiumhospitalet, Oslo, Norway
2002- 2005: Research assistant, Centre of Immunology Marseille-Luminy, France
2001- 2002: Research assistant, Institute for Cancer Research, Radiumhospitalet, Norway
1999- 2001: Research Assistant/Laboratory manager Dept. of Immunology, Rayne Institute, Kings College School of Medicine, London, UK
Awards
- F1000Research prize 2015 for outstanding presentation at PIVAC‐15 conference
- Inven2 Innovation award 2014: "A universal killer-T cell for personalized medicine"